About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Boston | 17,836 Studies Near You | Clareo Health

Clinical Trials LocationsBoston

Clinical Trials in Boston

Discover 17,836 clinical trials near Boston, Massachusetts. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 7141-7160 of 17,836 trials

WITHDRAWNPhase 2< 1 mile

Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)

NCT05269134

This is a study designed to evaluate bacteriophage therapy in patients with chronic prosthetic joint infections.

Prosthetic Joint Infection

Adaptive Phage Therapeutics, Inc.Started Mar 2023

San Diego, California, United States • Hartford, Connecticut, United States • Idaho Falls, Idaho, United States +7 more locations

COMPLETEDPhase 2< 1 mile

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

NCT00849290

This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)

Metastatic Androgen Independent Prostate Cancer

Dendreon113 participantsStarted Apr 2004

Los Angeles, California, United States • Los Angeles, California, United States • Sacramento, California, United States +55 more locations

Find Trials by Condition in Boston

Breast Cancerin Boston Lung Cancerin Boston Prostate Cancerin Boston Colorectal Cancerin Boston Melanomain Boston Leukemiain Boston Lymphomain Boston Pancreatic Cancerin Boston Ovarian Cancerin Boston Brain Cancerin Boston Diabetesin Boston

Data from ClinicalTrials.govTerms

TERMINATEDPhase 3< 1 mile

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

NCT04007367

This is a study with an Open-Label (OL) phase followed by a randomized, Double-Blind (DB), placebo-controlled phase to assess efficacy and safety of SAGE-217 on relapse prevention in adults with major depressive disorder (MDD).

Major Depressive Disorder

Biogen53 participantsStarted Aug 2019

Bentonville, Arkansas, United States • Bellflower, California, United States • Garden Grove, California, United States +43 more locations

COMPLETEDNA< 1 mile

Determinants of Vitamin K Metabolism

NCT00336232

The purpose of this study is to learn how the body responds to different amounts of vitamin K in the diet in order to understand the roles that vitamin K may have in the body. We also need to determine if older adults need more or less vitamin K in their diet compared to younger adults in order to maintain normal body stores of vitamin K.

AgingOsteoporosis

Tufts University59 participantsStarted May 2006

Boston, Massachusetts, United States

COMPLETEDPhase 2< 1 mile

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

NCT02181738

The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B \& C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.

Hodgkin Disease

Bristol-Myers Squibb294 participantsStarted Aug 2014

Los Angeles, California, United States • Los Angeles, California, United States • Atlanta, Georgia, United States +35 more locations

RECRUITING< 1 mile

The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

NCT06146725

There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is varied, amongst neurosurgeons internationally and at times even within an instiutition. This study aims to compare the effects of maximal tumor resection versus tissue biopsy on survival, functional, neurological, and quality of life outcomes in these patient subgroups. Furthermore, it evaluates which modality would maximize the potential to undergo adjuvant treatment. This study is an international, multicenter, prospective, 2-arm cohort study of observational nature. Consecutive HGG patients will be treated with resection or biopsy at a 3:1 ratio. Primary endpoints are: 1) overall survival (OS) and 2) proportion of patients that have received adjuvant treatment with chemotherapy and radiotherapy. Secondary endpoints are 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months and 6 months after surgery 2) progression-free survival (PFS); 3) quality of life at 6 weeks, 3 months and 6 months after surgery and 4) frequency and severity of Serious Adverse Events (SAEs). Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.

GlioblastomaGlioblastoma, IDH-wildtypeGlioblastoma Multiforme+2 more

Jasper Gerritsen564 participantsStarted Jan 2023

San Francisco, California, United States • Boston, Massachusetts, United States • Leuven, Belgium +5 more locations

RECRUITING< 1 mile

The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

NCT06146738

There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). This study aims to characterize the impact of palliative care versus biopsy versus resection on survival and quality of life in these patients. Also, it will aim to determine if there is a subset of patients that benefit the most from resection or biopsy, for which outcome, and how they could be identified preoperatively. This study is an international, multicenter, prospective, 3-arm cohort study of observational nature. Consecutive HGG patients will be treated with palliative care, biopsy, or resection at a 1:3:3 ratio. Primary endpoints are: 1) overall survival, and 2) quality of life at 6 weeks, 3 months and 6 months after initial presentation based on the EQ-5D, EORTC QLQ C30 and EORTC BN 20 questionnaires. Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.

GlioblastomaGlioblastoma MultiformeGlioblastoma, IDH-wildtype+1 more

Jasper Gerritsen1,015 participantsStarted Jan 2023

San Francisco, California, United States • Boston, Massachusetts, United States • Leuven, Belgium +5 more locations

COMPLETEDPhase 3< 1 mile

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

NCT04940390

Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.

MigraineMigraine With AuraMigraine Without Aura

Satsuma Pharmaceuticals, Inc.1,591 participantsStarted Jun 2021

Chandler, Arizona, United States • Phoenix, Arizona, United States • Tempe, Arizona, United States +124 more locations

TERMINATEDPhase 3< 1 mile

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

NCT03496623

The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil compared to placebo in improving exercise ability as measured by change from baseline in 6-Minute Walk Distance (6MWD) following 12 weeks of active treatment in participants with PH-COPD.

Pulmonary HypertensionChronic Obstructive Pulmonary Disease

United Therapeutics188 participantsStarted May 2018

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +73 more locations

COMPLETEDPhase 29.1 miles

Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain

NCT04529096

This study is being done to test the safety and efficacy of the study drug LY3016859 for the treatment of chronic low back pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Chronic Low-back Pain

Eli Lilly and Company149 participantsStarted Aug 2020

Birmingham, Alabama, United States • Chandler, Arizona, United States • Chandler, Arizona, United States +31 more locations

UNKNOWNPhase 221 miles

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06153342

In this prospective Phase 2, single-center, randomized, double-masked, placebo-controlled study, approximately 70 subjects with allergic conjunctivitis will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.

Allergic Conjunctivitis

Telios Pharma, Inc.70 participantsStarted Nov 2023

Andover, Massachusetts, United States

COMPLETEDPhase 323 miles

Assessing Clinical Outcomes in Alzheimer's Disease Agitation

NCT04797715

This is a multi-center, double-blind, placebo-controlled, randomized withdrawal study to evaluate the efficacy and safety of AXS-05 compared to placebo in the treatment of agitation symptoms in subjects with agitation associated with Alzheimer's disease.

Agitation in Patients With Dementia of the Alzheimer's TypeAlzheimer DiseaseAgitation,Psychomotor

Axsome Therapeutics, Inc.178 participantsStarted Dec 2020

Sun City, Arizona, United States • Tucson, Arizona, United States • Chula Vista, California, United States +60 more locations

TERMINATEDNA25 miles

Study To Assess Radiofrequency Diathermocontraction Device For Muscle Stimulation And The Treatment Of Abdominal Fat

NCT05388617

The intended use of the device in this study to assess the safety and efficacy of the adhesive electrodes for muscle stimulation and the treatment of abdominal fat on the abdomen and/or flanks.

Muscle StimulationAbdominal Fat

Cynosure, Inc.16 participantsStarted May 2022

Westford, Massachusetts, United States

UNKNOWN29 miles

Early Caries Lesion Management Observational Study

NCT04933331

The purpose of this observational study is to assess the effectiveness of Curodont Repair Fluoride Plus (CRFP) compared to other tooth-specific treatments (silver diamine fluoride (SDF), sealants, or other FDA-approved treatments) in preventing progression to cavitation in patients with at least one early non-cavitated dental caries lesion. The study will also evaluate the effectiveness of CRFP in comparison to no tooth-specific treatment control groups, including whole mouth treatments such as: 2.26% fluoride varnish, 1.23% fluoride foam, and 5000 ppm fluoride prescription toothpaste; and no treatment, on caries arrest and in preventing progression to cavitation in patients with at least one early non-cavitated dental lesion.

Initial CariesArrested Dental CariesCavitated Caries+2 more

CareQuest Institute for Oral Health744 participantsStarted Dec 2020

Dothan, Alabama, United States • Westborough, Massachusetts, United States • Bend, Oregon, United States +1 more locations

TERMINATEDPhase 339 miles

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

NCT03970837

This study \[contRAst 2 (201791: NCT03970837)\] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165 in combination with csDMARD(s), for the treatment of adult participants with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to csDMARD(s) or bDMARD(s). The study will consist of a screening phase of up to 6 weeks followed by a 52 week treatment phase in which participants will be randomized in a ratio of 6:6:3:1:1:1 to receive GSK3196165 150 milligrams (mg) subcutaneous (SC) weekly, GSK3196165 90 mg SC weekly, tofacitinib capsules (cap) 5 mg twice a day or placebo (three arms, each placebo arm will have 12 weeks placebo followed by 40 weeks active treatment) respectively, all in combination with csDMARD(s). Participants who, in investigator's judgement will benefit from extended treatment with GSK3196165 may be included in the long-term extension study \[contRAst X (209564: NCT04333147)\]. For those participants who do not continue into the long term-extension study, there will be an 8 week safety follow-up visit following the treatment phase.

Arthritis, Rheumatoid

GlaxoSmithKline1,764 participantsStarted Jun 2019

Flagstaff, Arizona, United States • Glendale, Arizona, United States • Mesa, Arizona, United States +266 more locations

COMPLETEDPhase 239 miles

ACP-01 in Patients With Critical Limb Ischemia

NCT02551679

The primary objective of this study is to determine the efficacy and safety of intramuscular injection of ACP-01, comprised of blood-derived autologous ACPs, in subjects with critical limb ischemia who are receiving standard of care therapy and have no endovascular or surgical revascularization options.

Critical Limb Ischemia

Hemostemix67 participantsStarted Aug 2014

Sacramento, California, United States • Aurora, Colorado, United States • Gainesville, Florida, United States +16 more locations

TERMINATEDPhase 244 miles

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

NCT05044234

Psoriasis is a chronic disease characterized by marked inflammation and thickening of the skin that results in thick, scaly skin plaques. This study assessed how safe and effective cedirogant (ABBV-157) was compared to placebo in adult participants with moderate to severe psoriasis. Efficacy and safety-related measurements assessed disease activity in participants with plaque psoriasis. Cedirogant (ABBV-157) is an investigational drug being developed for the treatment of chronic plaque psoriasis. Participants were put into 1 of 4 groups, called treatment arms and each group received a different treatment. There was a 1 in 4 chance that participants were assigned to placebo. Participants received oral daily doses of cedirogant or placebo capsules for 16 weeks. There may have been a higher burden for participants in this study compared to usual standard of care. Participants attended regular visits per routine clinical practice. The effect of the treatment was checked by medical assessments, checking for side effects, and questionnaires.

AbbVie156 participantsStarted Nov 2021

Birmingham, Alabama, United States • Phoenix, Arizona, United States • North Little Rock, Arkansas, United States +50 more locations

UNKNOWN179 miles

Pediatric Vasculitis Initiative

NCT02006134

Childhood chronic vasculitis describes a group of rare life-threatening diseases that have in common inflammation of blood vessels in vital organs such as kidneys, lungs and brain. Most knowledge about them comes from adult patients. Severe disease requires aggressive life-saving treatments with steroids and some cancer drugs which can themselves cause damage, and increase risks of cancer and severe infections. Conversely, milder disease can be treated with less toxic drugs. Different classification and "scoring tools" are used to define the types and severity of vasculitis and to measure damage caused by disease or drugs. These in turn help direct how aggressively to treat a patient and to measure outcome. None of these tools however have been assessed in children and the best balance of disease and treatment risks against outcome for children is not known. Although causes of these diseases in children and adults are probably the same, the effects of the disease and the response (good and bad) to drugs will differ in growing children. Because specialists may see only one new child with vasculitis each year, obtaining enough information to learn about childhood vasculitis requires cooperation. We will use an international web-based registry to which doctors from 50 or more centers can contribute patient data. We will determine the features which help better classify and diagnose children compared to adults. Through the web we will collect and analyze information on patients similarly classified and "scored" so that most successful treatments can be identified. Children with vasculitis are less likely to have diseases associated with aging, alcohol and smoking etc., and therefore may be a better group in whom to study the underlying biology of vasculitis. We will use this opportunity and collect spit, blood and tissue from registry patients for laboratory study with an aim to find biomarkers to better classify, define and direct optimal treatment and outcomes.

Wegeners Granulomatosis (Granulomatosis With Polyangiitis)Microscopic PolyangiitisEosinophilic Granulomatosis With Polyangiitis+4 more

University of British Columbia1,600 participantsStarted Jan 2013

San Francisco, California, United States • Gainesville, Florida, United States • Chicago, Illinois, United States +29 more locations

COMPLETEDPhase 2185 miles

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

NCT00355238

The purpose of this clinical research study is to learn if BMS-582664 can shrink or slow the growth of advanced liver cancer. The safety of this treatment will also be studied.

Hepatocellular Carcinoma (HCC)

Bristol-Myers Squibb137 participantsStarted Dec 2006

Duarte, California, United States • Duarte, California, United States • Los Angeles, California, United States +34 more locations

UNKNOWN2625 miles

Evaluation of VQm PHM on Pulmonary Health Parameters for ICU

NCT06147674

The goal of this observational study is to compare pulmonary health parameter measurements from the VQm PHM™ to existing clinical measurements. The main questions it aims to answer are: * Confirm the performance of non-invasive pulmonary health parameter shunt fraction value found on the VQm PHM™ when compared to available reference measurements. * Confirm the performance of non-invasive pulmonary health parameter pulmonary blood flow, functional residual capacity and physiological dead space found on the VQm PHM™ when compared to available reference measurements.

Ventilators, MechanicalStrokeCOPD+2 more

Rostrum Medical Innovations Inc.150 participantsStarted Jan 2024

Sacramento, California, United States • Vienna, Austria • Prague, Czechia +1 more locations

PreviousPage 358 of 892Next

Heart Diseasein Boston